Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Date:9/2/2008

w therapies that provide rapid onset of predictable effect and are delivered in a patient-friendly, non-invasive manner."

Phase 3 Clinical Trial Design

The AZ-004 clinical trial enrolled 344 schizophrenic patients with acute agitation at 24 U.S. clinical centers. The trial was designed as an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and tested AZ-004 at two dose levels, 5 mg and 10 mg. Patients were eligible to receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. Only one dose of study drug was allowed during the first 2 hours of the study period.

The primary endpoint for the study was the change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component score (also known as PEC score), measured at 2 hours after the first dose. The key secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) score, measured at 2 hours after the first dose. All results were considered statistically significant at the p < 0.05 level, as compared to placebo, and all analyses were made on an intent-to-treat basis. Various additional assessments of a patient's agitation state were conducted at serial time points using the PEC scale over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded for each patient throughout their 24-hour study period.

Primary Efficacy Endpoint

Both the 5 mg and the 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, showing a statistically significant improvement in the 2-hour post-dose PEC score, compared to placebo.

PEC Scores (Mean Values)

p-Value for Change

from Baseline

Study Arm Baseline 2-Hour Post-Dose vs. Placebo

10 mg AZ-004<
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... , September 3, 2014 , ... expert re-joins the Company ~   ... Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy ... Dr. Jeroen Rovers , MD PhD, as its ... recently Chief Medical Officer at Ceronco Biosciences. Prior to ...
(Date:9/3/2014)... BUDAPEST, Hungary , Sept. 3, ... PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: ... collaboration and license agreement to co-develop and commercialize ... the European Union, other European countries and additional ... company with a strong focus in female health ...
(Date:9/2/2014)... , Sept. 3, 2014  Edison Pharmaceuticals today ... placebo-controlled trial in pediatric patients. Rett syndrome patients ... in head circumference.  Decreased brain growth and head ... Rett syndrome is a genetic neurodevelopmental disorder ... 24 months of age. It is characterized by ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 2Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 3Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 4Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 5Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 2Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 3
... , the leading online Medical Transcription and Editing training ... NexGen Speech Recognition Editing and Medical Transcription Program. In ... MTEC is moving their curriculum to the next level. ... this important industry migration and is being provided to ...
... Medical Messenger , an innovative healthcare technology ... 4 is now certified to meet 2011-2012 criteria supporting ... and Reinvestment Act (ARRA) as a Complete EHR by ... record (EHR) software capable of enabling providers to meet ...
Cached Medicine Technology:MTEC Announces Release of NexGen Speech Recognition Editing and Medical Transcription Training Program 2Medical Messenger's AstralJet V4 Receives ONC-ATCB 2011/2012 Certification 2
(Date:9/3/2014)... 2014 CS3 Technology, a Sage North ... support of Sage 100 ERP, Sage 500 ERP, and ... Million Dollar Club achiever for surpassing a million dollars ... CS3 Technology and all Million Dollar Club achievers for ... Sage, its business partners and the mutual customers they ...
(Date:9/3/2014)... New Orleans, LA (PRWEB) September 03, 2014 ... 1st, at 201 ST. Charles, Suite 255B New Orleans, at ... this office. John was a litigation support manager at Baker ... Thompson & Knight LLP before joining LCI and has over ... for clients of all sizes. , LCI® began in the ...
(Date:9/3/2014)... 2014 Health information technology improves ... decreases medical errors, and strengthens the interaction between ... the important role health information technology plays in ... across the U.S. have joined together to celebrate ... 16-20, 2014. With the NHIT Week theme: One ...
(Date:9/3/2014)... Pwnie Express today announced the release of the ... R3, an inconspicuous pentesting device whose drop box form ... at a fraction of the cost of traditional penetration ... company to assess wired and wireless network security anywhere, ... penetration testing device in a portable, shippable, "Plug-and-Pwn" form ...
(Date:9/3/2014)... Immersion Active (ImmersionActive.com ), the digital agency for ... 2014 Content Marketing Awards presented by the Content Marketing ... program for people who create content for organizations. Categories ... , Immersion Active’s winning entry was the Alzheimer’s ... Senior Care®. This series addresses people who care for ...
Breaking Medicine News(10 mins):Health News:CS3 Technology Named a Sage Million Dollar Club Achiever for 2013-2014 2Health News:Grand Opening of Legal Concierge Inc.’s New Location 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Immersion Active Wins Silver for Email Strategy in 2014 Content Marketing Awards 2
... (Nasdaq: MEMY ) today announced the issuance ... matter patent,protection for a series of nicotinic alpha-7 ... which are both being developed,in partnership with Roche ... disease and cognitive impairment associated with schizophrenia,(CIAS). The ...
... Baby boomers are turning 62,every seven seconds. ... their,own health care in their senior years, says ... Care insurance lawyer., (Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02 ), ... Care. It has been sold and,marketed to our ...
... ConvergeWireless Inc., of Ontario Canada, a Value Added Wireless Application ... been certified by the AT&T Developer Program. MyMileageGenie & MyFormsGenie ... for Enterprise Sales. , ... Ontario, ...
... DETROIT, Oct. 24 For the second ... has been chosen as the most,preferred hospital ... to the,2008 Cancer Treatment Preference Profile Survey ... http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ), The annual survey, ...
... body, checking arteries lowers risk of further injury , , THURSDAY, ... is only the first step in saving a life after ... advisory, published in the Oct. 23 issue of Circulation ... resuscitation or risk the losing the patient to the original ...
... Alternext US: FIT), a leading provider of integrated,employee ... report financial results for the third quarter ended ... the market closes. The company will also,hold a ... results. Participating,in the call will be Dr. Gregg ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Expert Says Conseco Trust May Significantly Alter The Senior Health Care Market 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 3Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 4Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan 2Health News:Speedy Care After Heart Attack Key to Survival 2Health News:HealthFitness Corporation to Report 2008 Third Quarter Financial Results 2
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTT/1P chairs are recommended for ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: